Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

Completed · Phase 1

Conditions studied: Healthy Volunteers

In brief

A bioequivalence and food-effect study comparing two tablet formulations of tebipenem pivoxil hydrobromide (TBPM-PI-HBr) in healthy adult subjects.

Key facts

Study ID

NCT04421885

Run by

Spero Therapeutics

People needed

36

Starts

2020-06-01

Expected to finish

2020-07-29

Last updated by the study team

2020-08-12

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy, adult, male or female, 18 to 55 years of age
• Continuous non-smoker.
• Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2.
• Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs.
• Has suitable venous access for repeated blood sampling.
• A female of childbearing potential must agree to abstain from sexual activity that could lead to pregnancy.
• A female of non-childbearing potential.
• Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.

You may not qualify if…

• Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected to have during the conduct of the study.
• History or presence of clinically significant medical or psychiatric condition or disease.
• History of any illness that might confound the results of the study or poses an additional risk to the subject by their participation in the study.
• History of significant allergic disease requiring treatment.
• History or presence of alcoholism or drug abuse.
• History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds.
• History of known genetic metabolism anomaly associated with carnitine deficiency.
• Female subjects with a positive pregnancy test or who are lactating.
• Positive urine drug or alcohol results.
• Positive results for human immunodeficiency virus (HIV 1 and 2), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
• QTcF interval is > 460 msec (males) or > 470 msec (females) or has ECG findings deemed abnormal with clinical significance by the PI or designee at the screening visit.
• Estimated creatinine clearance < 80 mL/min at the screening visit.
• Unable to refrain from or anticipates the use of any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements.

Where it is running

• Medical Facility — Tempe, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.